Frontlight ResearchEarly access
Taking peopleNo phase
Fosfomycin I.v. for Treatment of Severely Infected Patients
Key facts
- Who runs it
- Infectopharm Arzneimittel GmbH
- Where
- Austria, Germany, Greece, Italy, and United Kingdom50 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- Dec 2016
- Expected to end
- Dec 2030
- Type of study
- Observational
- Record updated
- 1 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female patients aged ≥ 18 years
- Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v
- Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC
- Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)
Who cannot take part
- Previous documentation of the patient in the present study
- Patients with known hypersensitivity to fosfomycin or any of the excipients
- Failure of > 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney
- Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)
- Patients with involvement of fungi or mycobacteria in the targeted infection
- Patients participating in an interventional clinical trial
- Terminally ill patients
- Patients with "do not resuscitate order"
- Palliative treatment approach
- Fosfomycin treatment as 4th line treatment or at later stage
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.
- Publications
- Real-World Data on the Use of Intravenous Fosfomycin for the Treatment of Central Nervous System Infections: a Subgroup Analysis from the FORTRESS Study.Infectious diseases and therapy, 2026
- Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study.Infectious diseases and therapy, 2025
- Record updated
- 1 October 2024